Clinical trials: First Line Treatment
Breast Neoplasms, Neoplasms, Hormone-Dependent
The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (Fareston®), is more effective than another…
- Trial name
- NCT00097344
- Testing
- Atamestane, Toremifene, Letrozole
- Where
- 104 sites in United States, Bulgaria and 3 more
- Volunteers
- 842 people
- Sponsor
- Intarcia Therapeutics
Non-Small-Cell Lung Carcinoma, Liver Cancer
Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
This protocol is a single arm phase II multi-center trial evaluating the efficacy of Stereotactic Body Radiation Therapy (SBRT) in patients with oligometastatic non-small cell lung cancer (NSCLC) with response or stable disease…
- Conditions
- Non-Small-Cell Lung Carcinoma, Liver Cancer, Adrenal Cancer
- Trial name
- NCT01185639
- Testing
- stereotactic body radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Wake Forest University Health Sciences
Metastatic Breast Cancer
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Few data about the impact of emotional distress (ED) on treatment efficacy in patients with metastatic breast cancer (mBC) are available.
- Trial name
- EIRENE (NCT06994377)
- Testing
- ED and quality of life assessment
- Where
- 37 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- European Institute of Oncology
Delivery Uterine
Comparison Between 25 µg Vaginal Misoprostol vs Slow Release Pessary PGE2
For about 10% of pregnancies, it is necessary to induce delivery for medical reasons. Prostaglandins alone can be used to perform cervical ripening in cases of immature cervix.
- Trial name
- CYTOPRO (NCT01765881)
- Testing
- Misoprostol, Dinoprostone
- Where
- 4 sites in France
- Volunteers
- 1,700 people
- Sponsor
- University Hospital, Toulouse
Advanced Esophageal Squamous Carcinoma
Irinotecan Combined With Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial
Irinotecan, as one new agent used in advanced esophageal carcinoma, has been shown to be effective and safe in western studies. Different with westerns, squamous carcinoma is the main pathological type in china patients.
- Trial name
- NCT01051765
- Testing
- irinotecan/cisplatin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University
NSCLC
SHR-A1921 Combined With Adebrelimab in the Treatment of Advanced NSCLC Who Failed the Previous Standard First-line Treatment
This is a Phase II clinical study to evaluate the efficacy and safety of SHR-A1921 conbined with adebrelimab in advanced NSCLC who failed the previous first-line standard therapy.
- Trial name
- NCT06480136
- Testing
- SHR-A1921 injection and adebrelimab injection
- Volunteers
- 32 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Breast Cancer
Myocet Plus Endoxan for Older Patients With Breast Cancer
This study will evaluate the efficacy, safety and effect on quality of life of liposomal-encapsulated doxorubicin in combination with cyclophosphamide as first or second line treatment of older patients (≥ 70 years old) with…
- Trial name
- NCT01120171
- Testing
- Cyclophosphamide, Liposomal-encapsulated doxorubicin
- Where
- 11 sites in Greece
- Volunteers
- 64 people
- Sponsor
- Hellenic Oncology Research Group
Non-squamous Non-small Cell Lung Cancer
Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer
Multi-center, open, randomized (parallel) and comparative phase III. Eligible patients will receive bevacizumab + chemotherapy for a minimum of 4 cycles followed by bevacizumab (+ pemetrexed, if appropriate) maintenance therapy…
- Trial name
- 65plus (NCT00976456)
- Testing
- Bevacizumab + Pemetrexed, Bevacizumab + Pemetrexed + Carboplatin
- Where
- Germany
- Volunteers
- 271 people
- Sponsor
- PD Dr. med. Wolfgang Schuette
Breast Cancer Metastatic
Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer
This is a multicenter, prospective, randomized, open-label, controlled phase II study to test the addition of the CDK4/6 inhibitor ribociclib to anti-hormonal treatment as maintenance therapy in patients with disease control (at…
- Trial name
- AMICA (NCT03555877)
- Testing
- Ribociclib, Anastrozole, Letrozole
- Where
- Germany
- Volunteers
- 56 people
- Sponsor
- GBG Forschungs GmbH
Colorectal Cancer Metastatic
Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
To evaluate the efficacy and safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic…
- Trial name
- NCT06282445
- Testing
- Adebrelimab, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 36 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Urothelial Carcinoma, Anlotinib
Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma
Anlotinib is a novel oral multitarget tyrosine kinase inhibitor and primary targeted to VEGFR, FGFR, PDGFR and c-Kit. This study intends to assess the efficacy and safety of anlotinib combined with platinum/gemcitabine for first…
- Conditions
- Urothelial Carcinoma, Anlotinib, Urogenital Neoplasms, Cisplatin
- Trial name
- NCT05030077
- Testing
- Anlotinib, Cisplatin, Carboplatin
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Tianjin Medical University Second Hospital
Advanced or Metastatic Gastrooesophageal Carcinoma
Simvastatin Efficacy in ARID1A Mutated Advanced gastroESophageal Carcinoma Treated With Immunotherapy
The investigators hypothesize that simvastatin (SIM) may improve the efficacy of first- line Nivolumab and Oxaliplatin-based chemotherapy, extending progression-free survival (PFS) as compared with Nivolumab and chemotherapy…
- Trial name
- NCT07213557
- Testing
- standard nivolumab and oxaliplatin- based chemotherapy, simvastatin in combination with standard nivolumab and oxaliplatin-based chemotherapy
- Where
- Italy
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute, Naples
Locally Advanced Unresectable or Stage IV Colorectal Cancer
Stage IV Colorectal CA ALIMTA
Phase I: The primary objective of the Phase 1 portion of this study is to determine the Maximum tolerated dose and the recommended Phase 2 dose of ALIMTA plus oxaliplatin when given with folate and vitamin B-12 supplementation in…
- Trial name
- NCT00166465
- Testing
- ALIMTA plus Oxaliplatin versus Oxaliplatin plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Mayo Clinic
Extensive-stage Small-cell Lung Cancer
Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC
Though great progress has been made in the treatment of SCLC in recent years, only two PD-L1 therapies are currently approved, treatment options are limited, and patient survival remains to be further improved.
- Trial name
- NCT05668767
- Testing
- Surufatinib Durvalizumab EP/EC
- Volunteers
- 20 people
- Sponsor
- Beijing Chest Hospital
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab
This is an open-label, prospective, randomized, multicenter phase II trial that will evaluate the efficacy and safety of intermittent addition of cetuximab to a FOLFIRI-based first line therapy to patients with RAS (Rat…
- Trial name
- NCT04554836
- Testing
- Cetuximab, FOLFIRI
- Where
- 4 sites in Germany
- Volunteers
- 6 people
- Sponsor
- TheraOp
Colorectal Neoplasms
First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib
This is a study to evaluate the efficacy (effectiveness) and the safety of regorafenib when given in combination with chemotherapy mFOLFOX6 as first line therapy in patients with metastatic colorectal cancer (CRC).
- Trial name
- NCT01289821
- Testing
- Regorafenib (Stivarga, BAY73-4506), Oxaliplatin, Folinic acid
- Where
- 18 sites in United States, Australia and 5 more
- Volunteers
- 54 people
- Sponsor
- Bayer
Metastatic Breast Cancer
European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies
A retrospective observational analysis of de-identified data from a multinational medical record review to describe patient characteristics, treatment patterns, and effectiveness of palbociclib + AI as first-line therapy among…
- Trial name
- EUCHARIS (NCT05043506)
- Testing
- Palbociclib + aromatase inhibitor, Aromatase inhibitor
- Where
- 64 sites in Austria, Belgium and 5 more
- Volunteers
- 1,939 people
- Sponsor
- Pfizer
Non-Small Cell Squamous Lung Cancer, Brain Metastases
Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases
This study is a prospective, single-arm, phase II clinical study to evaluate the efficacy and safety of Tislelizumab Plus Chemotherapy in patients with squamous NSCLC with brain metastases who had not previously received systemic…
- Trial name
- NCT05207904
- Testing
- Tislelizumab, paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Sun Yat-sen University
Extensive-stage Small Cell Lung Cancer
A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer
This trial is a Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of QLC5508 in combination with QL2107 versus Tislelizumab plus platinum and etoposide as first-line treatment in…
- Trial name
- NCT07802821
- Testing
- QLC5508, QL2107, Tislelizumab
- Where
- China
- Volunteers
- 556 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Breast Cancer, Triple Negative Breast Cancer
Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer
This is the first part of a 2-part study assessing the efficacy of AZD2281 in combination with paclitaxel in 1st or 2nd line treatment of patients with metastatic triple negative breast cancer.
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT00707707
- Testing
- AZD2281, Paclitaxel
- Where
- 6 sites in Australia, Austria and 2 more
- Volunteers
- 19 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.